Last updated on April 21, 2014 at 5:04 EDT

Corindus Vascular Robotics Launches “CorPath® One Stent Program” for Hospital Cardiac Cath Labs

October 30, 2013

Financial credit provided if second stent is required in a CorPath robotic-assisted angioplasty

WALTHAM, Mass., Oct. 30, 2013 /PRNewswire/ — Corindus Vascular Robotics, a leading provider of precision medical robotics, today announced the launch of its CorPath One Stent Program. The goal of the program is to raise awareness of the potential to decrease longitudinal geographic miss (LGM) caused by sub-optimal stent placement, as well as the patient safety and financial benefits that can result from using the CorPath Vascular Robotic System to place just one stent per lesion in coronary angioplasty procedures. Corindus is offering a $1,000 credit to hospitals that use two or more stents per lesion in qualifying coronary angioplasties performed with the CorPath System.


“No matter how good we are as physicians, we are still human and imprecision in stent placement or stent size selection can occur,” said Dr. Ronald Caputo, Director of Cardiac Services and Cardiology Research at St. Joseph’s Hospital in Syracuse, NY, current CorPath user and participant in the CorPath PRECISE trial conducted in 2011. “Introducing CorPath into our cath lab has provided substantial benefits to both physicians and patients in terms of our ability to more accurately select the stent size and enhance dexterity in delivering it to a precise location. Ultimately, these capabilities may result in improved outcomes for the patient and an enhanced PCI procedure for the physician.”

Up to 47 percent of stents are not optimally positioned(1); in an attempt to avoid inferior clinical outcomes due to LGM, the CorPath System was designed to bring robotic precision to coronary angioplasty procedures and stent positioning.

“Although manual PCIs are widely accepted in cath labs across the country, robotic-assisted PCIs could provide some notable advantages over the current care paradigm,” notes Frost & Sullivan Medical Device Analyst Venkat Rajan. “As seen in other procedures, the introduction of robotic-assisted systems has often afforded specialists unparalleled control and precision when attempting critical life-saving procedures.”

PCI procedures performed in the U.S. use more than 1.2 stents per lesion, according to the national average(2); additional stenting can be caused by a number of factors, including challenges in visualizing the lesion, improper stent selection due to inaccurate lesion length assessment and misplacement of the stent during device delivery. In cases where more than one stent is used, the hospital’s procedure profitability is reduced substantially.

“The CorPath One Stent Program is evidence that Corindus stands behind their product and its potential to avoid excess stenting and provide significant financial and safety benefits to the hospital and the patient,” said John Cannizzaro, Cardiovascular Service Line Administrator at St. Joseph’s Hospital.

The CorPath System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter by millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

“Corindus is committed to improving procedural safety and efficiency for the clinician and the patient,” said David Handler, President and CEO of Corindus Vascular Robotics. “We are so confident that the CorPath System can provide both patient safety and financial benefits to hospital cardiac cath labs that we are willing to put our money behind our technology to position the right stent in the right place. That is the promise of the CorPath One Stent Program.”

Demonstrations of the CorPath System will take place at the Corindus booth (#1117) at the TCT (Transcatheter Cardiovascular Therapeutics) Annual Conference, Oct. 27 – Nov. 1, in San Francisco, Calif. To learn more about the CorPath One Stent Program, please visit www.corindus.com/onestent.

About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit www.corindus.com.


    [1] "Impact of stent
     deployment procedural
     factors on long-term
     effectiveness and safety
     of sirolimus-eluting
     stents (final results of
     the multicenter
     prospective STLLR trial),"
     Costa, MA. Am J Cardiol.
     2008 Jun 15;101(12):1704-
     11. Epub 2008 Apr 9.

    [2] "Keys to successful
     health care reform,"
     Goodroe Healthcare
     Solutions, 2009.

Media Contact:
KNB Communications
Brittny Quinn
203-504-8230 ext. 134

Related Links
Corindus Vascular Robotics

Image with caption: “Corindus Vascular Robotics Launches “CorPath® One Stent Program” for Hospital Cardiac Cath Labs.” Image available at: http://photos.prnewswire.com/prnh/20131030/MM06987-a

Image with caption: “Corindus Vascular Robotics Launches “CorPath® One Stent Program.” for Hospital Cardiac Cath Labs” Image available at: http://photos.prnewswire.com/prnh/20131030/MM06987-INFO-b

SOURCE Corindus Vascular Robotics

Source: PR Newswire